Sleep medicine最新文献

{"title":"Response to comment on “Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials”","authors":"Chia Siang Kow , Dinesh Sangarran Ramachandram , Syed Shahzad Hasan , Kaeshaelya Thiruchelvam","doi":"10.1016/j.sleep.2025.106709","DOIUrl":"10.1016/j.sleep.2025.106709","url":null,"abstract":"","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"Article 106709"},"PeriodicalIF":3.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144809337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between prescription medications and sleep duration, insomnia, and sleep apnea in US military service members","authors":"Joseph J. Knapik ,&nbsp;John A. Caldwell ,&nbsp;Ryan A. Steelman ,&nbsp;Daniel W. Trone ,&nbsp;Harris R. Lieberman","doi":"10.1016/j.sleep.2025.106707","DOIUrl":"10.1016/j.sleep.2025.106707","url":null,"abstract":"<div><h3>Study objectives</h3><div>This study examined associations between filled prescription medications (FPMs) and sleep duration, insomnia, and sleep apnea (SA).</div></div><div><h3>Methods</h3><div>Active-duty service members (SMs) (n = 20,819) completed a questionnaire on sleep, demographics, and lifestyle characteristics and permitted access to their pharmacy and medical records 6-months before questionnaire completion. FPMs were classified by American Hospital Formulary System Pharmacologic-Therapeutic Classification System (PTCS) codes and compared across sleep durations of ≥7, 5–6, and ≤4 h and among those with and without diagnosed insomnia and SA.</div></div><div><h3>Results</h3><div>Compared to SMs reporting ≥7 h sleep, those reporting 5–6 and ≤4 h had 1.19 (95 %confidence interval [95 %CI] = 1.12–1.27) and 1.69 (95 %CI = 1.45–1.97) times higher odds of a FPM, respectively, after adjustment for demographics and lifestyle characteristics. Compared to SMs reporting ≥7 h sleep, those reporting 5–6 h had higher adjusted odds of FPMs in 10 of 20 PTCS codes--particularly electrolyte/caloric/water-balance agents--and those reporting ≤4 h had higher odds in 13 of 20 PTCS codes--particularly cardiovascular and central nervous system (CNS) agents. SMs with insomnia or SA had 8.66 (95 %CI = 5.89–12.71) and 3.46 (95 %CI = 2.90–4.12) higher adjusted odds of an FPM compared to those without insomnia or SA, respectively. SMs with insomnia or SA had higher adjusted odds of FPMs in 16 and 18 of 20 PTCS codes compared to those without these diagnoses. Cardiovascular and CNS agents were most prevalent in both sleep-disordered groups.</div></div><div><h3>Conclusion</h3><div>Filling prescriptions in many different classes of medications increased as sleep duration decreased and was higher among SMs with diagnosed insomnia or SA.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"Article 106707"},"PeriodicalIF":3.4,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144772074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solriamfetol for the treatment of excessive daytime sleepiness in participants with obstructive sleep apnea with different levels of adherence to primary OSA therapy: Subgroup analysis of a randomized clinical trial","authors":"Jiucheng Shen ,&nbsp;Kaida Guo ,&nbsp;Jing Wang ,&nbsp;Zhijun Wang ,&nbsp;Shiyuan Gao ,&nbsp;Qiaojun Wang ,&nbsp;Fei Han ,&nbsp;Weijia Zhang ,&nbsp;Xiang Li ,&nbsp;Hui Ye ,&nbsp;Rui Chen","doi":"10.1016/j.sleep.2025.106706","DOIUrl":"10.1016/j.sleep.2025.106706","url":null,"abstract":"<div><h3>Background</h3><div>Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). The current study aims to evaluate effects of solriamfetol among participants with different adherence to primary OSA therapy using data from a randomized clinical trial conducted among Chinese participants.</div></div><div><h3>Methods</h3><div>Participants were 1:1 randomized to placebo or solriamfetol (up to 150 mg/day) for 12 weeks (stratified by adherence to primary OSA therapy). The coprimary endpoints were change from baseline in mean sleep latency of maintenance of wakefulness test (MWT) and Epworth Sleepiness Scale (ESS) at week 12 in the full analysis set. Use of primary OSA therapy and safety were also evaluated.</div></div><div><h3>Results</h3><div>At baseline, of all participants, around 50 % were adherent, 20 % were non-adherent and 30 % were not on primary OSA therapy, respectively. In all subgroups, solriamfetol treatment was associated with significant or numerical improvement in MWT sleep latency or ESS (LS mean difference vs. placebo, p &lt; 0.05 except ESS in non-adherence to primary therapy subgroup). Use of primary OSA therapy was stable throughout the 12-week study. Solriamfetol was well tolerated and the most common TEAEs included metabolism and nutrition disorders, upper respiratory tract infection, dizziness, hypertension and elevated blood creatine phosphokinase.</div></div><div><h3>Conclusion</h3><div>In the subgroup analysis of a randomized clinical trial in Chinese OSA participants with EDS, solriamfetol was effective and well tolerated regardless of adherence to primary OSA therapy. No clinically meaningful impact of solriamfetol on the use of primary OSA therapy was found.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"Article 106706"},"PeriodicalIF":3.4,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144763832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of obstructive sleep apnea in patients with asthma or allergic rhinitis: a systematic review and meta-analysis","authors":"Nuno Barros Ferreira ,&nbsp;Alexandra Ponte ,&nbsp;Ana Castelo Grande ,&nbsp;Ana Cláudia Pimenta ,&nbsp;Cláudia Sofia Pinto ,&nbsp;Jean Bousquet ,&nbsp;Marta Drummond ,&nbsp;Bernardo Sousa-Pinto","doi":"10.1016/j.sleep.2025.106705","DOIUrl":"10.1016/j.sleep.2025.106705","url":null,"abstract":"<div><h3>Background</h3><div>Asthma and allergic rhinitis (AR) are prevalent respiratory diseases that often coexist with obstructive sleep apnea (OSA). The objective of this study was to evaluate whether asthma or AR are associated with a higher frequency of OSA.</div></div><div><h3>Methods</h3><div>We performed a systematic review including cross-sectional and cohort studies that evaluated adult participants with and without asthma or AR and reported OSA diagnosed via polysomnography. We searched PubMed, Web of Science, and Scopus. Risk of bias was assessed using the ROBINS-E tool. Certainty of evidence was evaluated using the GRADE Framework. A random-effects meta-analysis of odds ratios (OR) to quantify the association between asthma or AR and OSA was performed.</div></div><div><h3>Results</h3><div>We included 12 studies (N = 19,203 participants). The meta-analysis indicated a higher frequency of OSA in AR patients (OR = 2.4; 95 %CI = 1.1; 5.3) compared to patients without the disease. In overall patients with asthma, the association with OSA (OR = 1.4; 95 %CI = 0.9; 2.2) was weaker than that observed in patients with moderate to severe asthma (OR = 10.1; 95 % CI = 1.3; 81.7). Patients with asthma exhibited slightly higher apnea-hypopnea index and oxygen desaturation index, along with lower mean oxygen saturation, compared to patients without asthma.</div></div><div><h3>Conclusions</h3><div>This meta-analysis identified an association between AR or asthma (particularly moderate to severe asthma) and OSA. Future research should address risk assessment of OSA for asthma and AR patients through prospective cohort studies, controlling for referral bias and asthma severity.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"Article 106705"},"PeriodicalIF":3.4,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144780825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential marker of brain impairment secondary to obstructive sleep apnea: The brain asymmetry","authors":"Jianhong Liao ,&nbsp;Yunhan Shi ,&nbsp;Xiaotian Zhu ,&nbsp;Yanru Li ,&nbsp;Demin Han","doi":"10.1016/j.sleep.2025.106701","DOIUrl":"10.1016/j.sleep.2025.106701","url":null,"abstract":"<div><h3>Background</h3><div>Obstructive sleep apnea (OSA) is one of the leading causes of sleep disorders and often exhibits psychological impairments. Brain asymmetry (BA), a recognized marker of psychological traits, has been found to be significantly elevated in OSA and associated with anxiety and personality traits. However, evidence for a causal relationship between BA and respiratory events remains lacking.</div></div><div><h3>Methods</h3><div>Patients undergoing polysomnography at the Sleep Medicine Center were enrolled in this study. Subsequently, sleep apnea or hypopnea with a duration of &gt;15 s and intervals of &gt;20 s were extracted and analyzed for BA changes during peri-respiratory events periods. Differences in power spectrum density in bilateral EEG activity were calculated for the frontal, central, and occipital regions.</div></div><div><h3>Results</h3><div>A total of 71 subjects were included in the study and 6445 respiratory events were extracted. We obtained 1265 respiratory events in N1, 3655 in N2, 62 in N3, and 1463 in REM. In frontal, BA was elevated during the event and recovered at the end of the event (<em>P&lt; 0.0001</em>), with a uniform pattern across bands. In central, respiratory events similarly induced BA (<em>P&lt; 0.0001</em>). In the occipital region, a decrease in BA was observed during respiratory events and a sudden rise at the end of the event (<em>P&lt;0.001</em>). Non-severe and severe OSA exhibit similar trends. In addition, subgroup analyses indicated alpha, beta and gamma as the main contributors to BA fluctuations.</div></div><div><h3>Conclusions</h3><div>Our findings suggest respiratory events trigger BA across brain regions. These findings, combined with previous studies, suggest BA may be a marker and characteristic phenotype of neurological dysfunction in OSA.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"Article 106701"},"PeriodicalIF":3.4,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144780828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of mPFC-rTMS in chronic Insomnia: A randomized, double-blind, placebo-controlled study","authors":"Jingjing Sun ,&nbsp;Panpan Li ,&nbsp;Yun Yi ,&nbsp;Wenyue Xu,&nbsp;Guanghua Zhang,&nbsp;Bidan Zhang,&nbsp;Kaimo Ding,&nbsp;Si Luo,&nbsp;Juanjuan Zhou","doi":"10.1016/j.sleep.2025.106704","DOIUrl":"10.1016/j.sleep.2025.106704","url":null,"abstract":"<div><h3>Background</h3><div>Medial prefrontal cortex (mPFC) may play an important role in the pathophysiological mechanism of insomnia and may be a potential target for treating insomnia. Herein, we aimed to investigate the efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) for chronic insomnia.</div></div><div><h3>Methods</h3><div>We conducted a pilot, double-blind, randomized, sham-controlled trial. 62 participants with chronic insomnia were recruited and randomly allocated to either the active or sham rTMS group. Forty-one patients completed 20 sessions of active or sham intervention targeting the mPFC and assessments at baseline, end of intervention, and follow-up.</div></div><div><h3>Results</h3><div>After 4-week intervention, the response rate and remission rate were significantly higher in the active group (51.7 % and 44.8 %) than those in the sham group (20.8 % and 16.7 %), with p = 0.037 and p = 0.048, respectively. At 4-week follow-up, the response rate and remission rate were not different between groups. There were significant interaction between group and time for insomnia severity using Pittsburgh Sleep Quality Index (PSQI) and sleep onset latency, daily disturbances, and hypnotic drug use. Post hoc analysis revealed that, compared with the sham group, the active group showed significant improvements in insomnia symptoms (except for total sleep time and sleep efficiency) at the end of the 4-week intervention, and significant improvements in PSQI scores, sleep onset latency, sleep efficiency, daily disturbances and hypnotic drug use at the 4-week follow-up. There were no statistically significant difference in adverse events between the two groups, and there were no serious adverse events occurred during treatment.</div></div><div><h3>Conclusion</h3><div>mPFC-rTMS maybe an effective and safety therapeutic in chronic insomnia.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"Article 106704"},"PeriodicalIF":3.4,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144781423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additive interactions of sleep disorders, insufficient sleep, and shift work on road and workplace safety incidents: A sufficient cause approach with overlap weights","authors":"Kelly Sansom ,&nbsp;Murthy N. Mittinty ,&nbsp;Claire Dunbar ,&nbsp;Andrew Vakulin ,&nbsp;Robert J.T. Adams ,&nbsp;Nigel McArdle ,&nbsp;Peter R. Eastwood ,&nbsp;Amy Reynolds","doi":"10.1016/j.sleep.2025.106699","DOIUrl":"10.1016/j.sleep.2025.106699","url":null,"abstract":"<div><h3>Background</h3><div>Behavioural and biological factors impacting healthy sleep can influence road and workplace safety. This study investigated the additive interactions of sleep-disrupting factors (sleep disorders, insufficient sleep, and shift work) on road and workplace safety in young adults (22 years) from the Raine Study.</div></div><div><h3>Methods</h3><div>Employed participants (n = 439, median age 22.0 years, IQR 21.6–22.3) were assessed for common sleep disorders (obstructive sleep apnoea, insomnia, restless legs syndrome). They provided information on shift work status, habitual sleep duration (insufficient sleep &lt;7 h), and self-reported road and work incidents. A sufficient cause approach with inverse probability of overlap weights and logistic regression was used to study additive interactions.</div></div><div><h3>Results</h3><div>Sleepiness while driving was reported by 16 % and while at work by 11 % of participants. Insufficient sleep alone increased the odds of falling asleep while driving (OR 2.29; 95 % CI 1.17, 4.32). Three sleep-disrupting factors additively increased the risk of near-miss road incidents (β, 1.40 &gt; 0). Sleep disorders with shift work was associated with the highest risk of falling asleep at work (relative excess risk due to interaction, RERI; 4.86; 95 % CI, 2.9, 6.81).</div></div><div><h3>Conclusion</h3><div>The combined burden of multiple sleep-disrupting factors including sleep disorders, insufficient sleep and shift work, is associated with an increased risk of near-miss road incidents and falling asleep at work. Given that sleepiness, both on the road and in the workplace, is common in young adults, there is a need for greater awareness and intervention to address the associated risks.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"Article 106699"},"PeriodicalIF":3.4,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep disordered breathing symptoms in children: a prospective evaluation 5 years after maxillary expansion","authors":"Nathalie Nietvelt ,&nbsp;Guy Willems ,&nbsp;Bertien Buyse ,&nbsp;Valentine Detailleur ,&nbsp;Maria Cadenas de Llano-Pérula","doi":"10.1016/j.sleep.2025.106700","DOIUrl":"10.1016/j.sleep.2025.106700","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the effects of maxillary expansion and of different types of subsequent comprehensive orthodontic treatment on sleep disordered breathing (SDB) symptoms in children five years after maxillary expansion.</div></div><div><h3>Methods</h3><div>Children needing early maxillary expansion were asked to fill the Pediatric Sleep Questionnaire (PSQ) at three time points: before the start of maxillary expansion (T0; N = 404), after active expansion (T1; N = 309) and after the completion of comprehensive orthodontic treatment (T2; N = 113). Maxillary expansion was achieved using a removable expansion plate (80,49 %), a hyrax (18,03 %) or a quadhelix (1,48 %). When indicated, comprehensive orthodontic treatment either consisted of fixed appliances alone or was combined with a class II functional appliance, a headgear or a hyrax. Linear mixed models corrected for age were used to compare the PSQ results per time point.</div></div><div><h3>Results</h3><div>Significant reductions in the total PSQ scores (p &lt; 0.0001), breathing (p &lt; 0.0001), behavior (p = 0.0026) and loudness of snoring (p = 0.0107) were observed between T0 and T1, which maintained between T0 and T2 (p = 0.0275; p = 0.0281; p = 0.0243). Between T1 and T2 and T0 and T2, sleepiness significantly increased (p &lt; 0.0001; p = 0.0004).</div><div>No significant interaction was found between the four different types of comprehensive orthodontic treatment and the PSQ scores.</div></div><div><h3>Conclusion</h3><div>Early maxillary expansion with removable plates has general a positive effect on PSQ scores. These improvements exhibit a stability for at least five years, regardless of the type of subsequent comprehensive orthodontic treatment. Therefore, the orthodontist plays an important role in the early detection and multidisciplinary treatment of pediatric obstructive sleep apnea syndrome.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"Article 106700"},"PeriodicalIF":3.4,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adaptation and validation of the adolescent sleep hygiene scale for Spanish-speaking populations","authors":"A. Muñoz-Alonso ,&nbsp;M. Romero-Saldaña ,&nbsp;F.J. Rodríguez-Cortés ,&nbsp;C. Rodríguez-Garriguet ,&nbsp;M. Carretero-Serrrano ,&nbsp;C. Rivas-Cruces ,&nbsp;M.I. Tovar-Gálvez ,&nbsp;P.J. López-Soto","doi":"10.1016/j.sleep.2025.106685","DOIUrl":"10.1016/j.sleep.2025.106685","url":null,"abstract":"<div><div>The school environment is essential for forming healthy habits, and having validated scales measuring sleep and wakefulness behaviours is critical for addressing adolescent sleep hygiene. Validation of such tools enables us to accurately assess sleep habits and design and implement more effective interventions that enhance young people's well-being and academic performance. This study aimed to adapt and culturally validate the Adolescent Sleep Hygiene Scale (ASHS) for Spanish-speaking adolescents, ensuring that the included items adequately reflected this population's cultural practices and sleep habits. Content validation was performed by a group of 45 expert judges, ensuring that the items were relevant and appropriate from a professional perspective. Subsequently, a pilot study was conducted with a sample of 255 adolescents, which allowed us to validate the scale construct robustly. The results of this study confirm that the ASHS is a valid and reliable tool that accurately reflects the sleep habits of Spanish adolescents. The translation and cultural validation of the ASHS represent a significant advance in promoting sleep hygiene among this vulnerable population, facilitating the identification of sleep-related problems and thereby contributing to improved health and academic performance among young people.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"Article 106685"},"PeriodicalIF":3.8,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144713823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dreem headband performance in Insomnia Disorder: An in-lab comparison to polysomnography","authors":"Qiutian A.L. Beau ,&nbsp;Johanna M. Boardman ,&nbsp;Alix Mellor ,&nbsp;Rowan P. Ogeil ,&nbsp;Sean P.A. Drummond","doi":"10.1016/j.sleep.2025.106698","DOIUrl":"10.1016/j.sleep.2025.106698","url":null,"abstract":"<div><h3>Background</h3><div>Capturing sleep data historically required complex, expensive, and labour-intensive equipment, with the gold standard being overnight polysomnography (PSG). Newer portable devices, such as the Dreem 3 headband, provide a novel opportunity to collect field-based data and have demonstrated accuracy in healthy sleepers compared to PSG. However, this device's performance has not been assessed in Insomnia Disorder, despite sleep-tracking technologies traditionally performing poorly in disordered sleepers. This study aimed to evaluate the performance of Dreem 3 against PSG on key sleep outcomes.</div></div><div><h3>Methods</h3><div>Thirty-one adults (<em>M</em>_<em>age</em> = 45.9 years, 16 males) with Insomnia Disorder participated in an overnight sleep study wearing Dreem 3 and PSG simultaneously. Sensitivity and specificity were calculated using an epoch-by-epoch analysis. Bland-Altman plots further assessed performance related to sleep stages and continuity variables: total sleep time (TST), sleep efficiency (SE), sleep latency (SL), and wake after sleep onset (WASO).</div></div><div><h3>Results</h3><div>Dreem 3 showed the highest sensitivity for REM sleep (89.88 %) and the lowest sensitivity for N1 (29.79 %). N3 sensitivity was also notably low (65.65 %). Specificity was &gt;90 % for all stages, except N2 (83.39 %). Dreem accurately summarised SL and WASO but significantly overestimated TST and SE.</div></div><div><h3>Conclusion</h3><div>The Dreem 3 headband can accurately evaluate and report most sleep staging and continuity variables in individuals with Insomnia Disorder. Users should be mindful of the strengths and limitations of the device when deciding whether the Dreem 3 is suitable for their needs. If applied and interpreted correctly, this device could facilitate large-scale, longitudinal sleep studies and assessment of sleep in Insomnia Disorder.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"Article 106698"},"PeriodicalIF":3.8,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144696820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}